Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Akeso Forms $100 Million JV with CTTQ to Develop PD-1 Candidate

publication date: Jun 20, 2019

Akeso Pharma of Zhongshan formed a $100 million JV with Chia Tai Tianqing Pharma (CTTQ), a subsidiary of Sino Biopharma, to develop and commercialize its clinical-stage anti-PD-1 mAb. CTTQ will contribute $50 million to the JV for a 50% stake. Akeso will add marketing rights to AK105, IP and technology for its half. CTTQ will be in charge of marketing the immunotherapy. According to Akeso, clinical tests of AK105 have shown it has better anti-tumor cell activity than its competitors. AK105 is also approved to start US trials. More details....

Stock Symbol: (HK:1177)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here